Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events Source: Eur Respir J 2015; 45: 1108-1118 Year: 2015
The pro-apoptotic effect of cysteinyl leukotriene receptor (CysLT-R) antagonist montelukast is mediated by CysLT-Rs expression on antigen-stimulated T cells Source: Eur Respir J 2003; 22: Suppl. 45, 100s Year: 2003
Generation and activation of myeloid derived suppressor cells using prostaglandin E2 and EP receptor agonists in vitro Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
Serotonin (5-hydroxytryptamine) modulates cytokine and chemokine production in lipopolysaccharide-primed human monocytes via stimulation of different 5-HT receptor subtypes Source: Annual Congress 2005 - Inflammation and remodelling in allergy and asthma Year: 2005
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Cysteinyl leukotriene receptor antagonist regulates vascular permeability by reducing VEGF expression Source: Eur Respir J 2004; 24: Suppl. 48, 129s Year: 2004
Elevated expression of adenosine A1 receptor in bronchial biopsy specimens from asthmatic subjects Source: Eur Respir J 2008; 31: 311-319 Year: 2008
Increased expression of the cysteinil leukotriene 1 receptor (CysLT1-R) in the bronchial epithelium of smokers Source: Eur Respir J 2001; 18: Suppl. 33, 74s Year: 2001
GB001, a selective prostaglandin D2 receptor 2 antagonist, blocks signaling in the peripheral blood of healthy subjects Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020
Expression and activity of bradykinin B2 receptor (B2R) in human airway fibroblast (HAFbs): a role in asthma remodeling Source: Eur Respir J 2006; 28: Suppl. 50, 748s Year: 2006
Nicotinic alpha-7 receptor stimulation (a7nAChR) inhibited NF-kB/STAT3/SOCS3 pathways in a murine model of asthma. Source: International Congress 2017 – Novel mechanisms and treatments for asthma Year: 2017
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Effect of leukotriene receptor antagonist on expression and variation of TGF-beta in T lymphocyte for mild persistent asthma in children Source: Annual Congress 2011 - Treating childhood asthma Year: 2011
Prostanoid DP1 receptor as a target for respiratory diseases Source: Eur Respir J 2005; 26: Suppl. 49, 214s Year: 2005
Effect of AVE5883, a dual NK1/NK2 receptor antagonist, on airway responsiveness to neurokinin A in asthma Source: Eur Respir J 2004; 24: Suppl. 48, 219s Year: 2004
Bronchoconstriction induced by prostaglandin D2 (PGD2 ) in guinea pig lung is enhanced by selective COX-2 inhibition Source: Eur Respir J 2006; 28: Suppl. 50, 759s Year: 2006
Fevipiprant inhibits eosinophil activation induced by multiple metabolites of prostaglandin D2 Source: International Congress 2019 – COPD, asthma and rhinitis: from cellular mechanisms to patients’ clinical responses Year: 2019
Upregulation of cysteinyl leukotriene receptors CysLT1 and CysLT2 by TGF-β1 and LTE4 on human bronchial epithelial cells Source: Annual Congress 2006 - Airway epithelial cells in inflammation Year: 2006
Cysteinyl leukotriene-induced upregulation of tenascin and laminin β2 chain in human bronchial epithelial cells is mediated by the CysLT1 receptor Source: Eur Respir J 2007; 30: Suppl. 51, 217s Year: 2007
EP2 & EP4 receptor agonists inhibit the airway sensory nerves that cause cough, a potential protective control that is lost in human smokers and a pre-clinical COPD model Source: International Congress 2017 – Novel mechanisms and treatments for COPD Year: 2017